Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00554190
Recruitment Status : Completed
First Posted : November 6, 2007
Results First Posted : April 23, 2009
Last Update Posted : April 23, 2009
Information provided by:
Carbylan Therapeutics, Inc.

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single (Participant);   Primary Purpose: Treatment
Conditions: Ethmoid Sinusitis
Interventions: Device: AdvaCoat sinus gel
Device: Merogel Injectable

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
First subject treatment: May 2007. Last subject treatment: December 2007.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 29 subjects were treated. Nineteen subjects were followed through 60 days post-treatment.

Reporting Groups
AdvaCoat and Merogel AdvaCoat compared to Merogel Injectable. Subjects were randomized to receive AdvaCoat applied to the right or left middle meatus tissues and Merogel applied to the middle meatus tissues on the opposite side.

Participant Flow:   Overall Study
    AdvaCoat and Merogel
STARTED   29 [1] 
COMPLETED   19 [2] 
Termination forms not completed                10 
[1] 29 subjects treated.
[2] 10 subjects did not complete the Termination Study Forms

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
AdvaCoat and Merogel Injectable AdvaCoat compared with Merogel Injectable

Baseline Measures
   AdvaCoat and Merogel Injectable 
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   29 
>=65 years   0 
[Units: Years]
Mean (Standard Deviation)
 42  (14.5) 
[Units: Participants]
Female   14 
Male   15 
Region of Enrollment 
[Units: Participants]
United States   29 

  Outcome Measures

1.  Primary:   Number of Participants With Adhesion as Measured by the Synechia (Adhesion) Scale   [ Time Frame: Post-operative through 60 days ]

2.  Primary:   Number of Participants With Solicited and Recorded Adverse Events   [ Time Frame: Post-operative through 60 days ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Marcee Maroney, VP Clinical Affairs
Organization: Carbylan BioSurgery Inc.
phone: 650 855 6774

Responsible Party: Marcee Maroney, V.P. Marketing and Clinical Affairs, Carbylan BioSurgery, Inc. Identifier: NCT00554190     History of Changes
Other Study ID Numbers: ACOT 1.0
First Submitted: November 2, 2007
First Posted: November 6, 2007
Results First Submitted: November 14, 2008
Results First Posted: April 23, 2009
Last Update Posted: April 23, 2009